Syncona Limited Total Voting Rights

RNS Number : 5124G

Syncona Limited

01 October 2024

 

Syncona Limited

Total Voting Rights

1 October 2024

Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 30 September 2024 the total number of ordinary shares in issue stands at 672,214,632. The Company holds 33,148,638 ordinary shares in treasury which attract no voting rights.

Therefore, the total number of voting rights in the Company is 639,065,994. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries

 

Syncona Ltd

Natalie Garland-Collins / Fergus Witt
Tel: [phone]

 

Deutsche Numis

Nathan Brown

Freddie Barnfield

Tel: [phone]

 

FTI Consulting

Ben Atwell / Tim Stamper

Tel: [phone] 

 

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

 

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TVRFLFLVIRLLIIS